SCHEMBL3461189

SCHEMBL3461189

COCCOc1cc2ccccc2nn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.64
TSHR P16473 2/20 0.49
KDM1A O60341 3/20 0.39
MPO P05164 1/20 0.39
TLR8 Q9NR97 6/20 0.39
LMNA P02545 1/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 2/20 0.37
CYP1A2 P05177 1/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PI4KA P42356 1/20 0.36
PIK3CG P48736 1/20 0.36
PI4KB Q9UBF8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639437 0.81 KDM4E (0.65) KDM4ETLR8ALDH1A1MAPTCYP1A2
SCHEMBL28249502 0.81 TLR8 (0.57) KDM4ETSHRTLR8
SCHEMBL1641167 0.78 KDM4E (1.00) KDM4ETLR8LMNAALDH1A1MAPT
SCHEMBL30315534 0.78 KDM4E (1.00) KDM4ETLR8LMNAALDH1A1MAPT
SCHEMBL9189248 0.78 KDM4E (0.51) KDM4ETLR8LMNAMAPTKMT2A
SCHEMBL27696506 0.76 MAPT (0.59) KDM4ETSHRKDM1AMPOTLR8
SCHEMBL13134303 0.74 THRB (0.54) KDM4ETSHRALDH1A1MEN1KMT2A
SCHEMBL8560716 0.73 TSHR (0.49) KDM4ETSHRKDM1AALDH1A1MAPT
SCHEMBL28293113 0.72 TSHR (0.59) KDM4ETSHRKDM1ATLR8LMNA
Hydrochloric Acid SCHEMBL28059935 0.72 NCF1 (0.49) KDM4ETSHRMPOALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723337-B2 3-cinnolinecarboxamide derivatives and their use for treating cancer ASTRAZENECA AB (SE) 2010-05-25 US disclosed
US-20090012084-A1 3-CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER ASTRAZENECA AB (SE) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012084-A1 3-CINNOLINECARBOXAMIDE DERIVATIVES AND THEIR USE FOR TREATING CANCER CSF3R, CSF1R, KIT KDM4E 2188/4885TSHR 3316/4885KDM1A 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.